Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISTARIL vs APOMORPHINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
Non-ergoline dopamine agonist with high affinity for D2 and D3 receptors, moderate affinity for D4, D5, and adrenergic receptors; activates striatal dopamine receptors to improve motor function.
Anxiety and tension associated with psychoneurosis,Pruritus due to allergic conditions (e.g., urticaria, atopic dermatitis),Sedation prior to dental or surgical procedures,Nausea and vomiting (off-label)
FDA: Acute treatment of hypomobility episodes ('off' episodes) in Parkinson disease,Off-label: Refractory erectile dysfunction, treatment of levodopa-induced dyskinesias, depression
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
Subcutaneous injection: 0.2 m L (2 mg) test dose, then 0.2-0.6 m L (2-6 mg) as needed for acute hypomobility episodes; maximum single dose 0.6 m L (6 mg). Sublingual: 2-10 mg sublingually as needed, not more than every 2 hours, maximum 30 mg/day. Continuous subcutaneous infusion: 0.5-2.0 mg/hour via infusion pump.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Terminal elimination half-life is 40–60 minutes in adults with normal renal function; prolonged to 3–6 hours in end-stage renal disease.
Primarily hepatic via CYP3A4 and CYP2D6; major metabolites include cetirizine.
Hepatic via CYP3A4, CYP2C9, and CYP2C19; main metabolite is apomorphine-8-O-sulfate; first-pass effect with rapid clearance.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Approximately 90% of an intravenous dose is excreted in urine within 24 hours, primarily as unchanged drug and sulfate conjugates. Biliary/fecal excretion is minimal (<5%).
Highly protein-bound: approximately 89-93%, primarily to albumin.
Approximately 90–99% bound, primarily to albumin.
Volume of distribution: 7-10 L/kg, indicating extensive tissue distribution.
1.8–2.5 L/kg, indicating extensive tissue distribution.
Oral: incomplete bioavailability due to first-pass metabolism, estimated at 40-60%; IM: nearly complete (85-100%).
Subcutaneous: 100% (absolute); sublingual: 16–18%; oral: <1% due to extensive first-pass metabolism.
No specific adjustment; use with caution in severe renal impairment due to potential accumulation of metabolites.
No dose adjustment for mild to moderate impairment. Severe impairment (GFR <15 m L/min): avoid use as apomorphine is renally eliminated and accumulation may occur; use with caution and reduce dose if necessary at GFR 15-29 m L/min.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A and B: no dose adjustment necessary. Child-Pugh C: pharmacokinetics not studied; use with caution and monitor closely.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 50 mg per dose (≤12 years); IM: 0.5-1 mg/kg every 4-6 hours.
Safety and efficacy not established; no pediatric dosing recommendations.
Start at lower end of dosing range (e.g., 25 mg oral 3-4 times daily); monitor for sedation and anticholinergic effects.
Elderly patients may be more sensitive to neuropsychiatric effects; initiate at low end of dosing range (e.g., 1-2 mg subcutaneously) and titrate slowly; monitor for hypotension and falls.
No FDA black box warning.
None.
May cause QT prolongation; use with caution in patients with risk factors (e.g., electrolyte imbalance, concomitant QT-prolonging drugs),Sedation and impaired cognitive/motor function; avoid driving or hazardous activities,Anticholinergic effects (e.g., urinary retention, constipation); use cautiously in elderly or patients with prostatic hypertrophy,Respiratory depression with concurrent CNS depressants,Use in pregnancy: avoid especially during early pregnancy; may increase risk of fetal abnormalities
Risk of hypotension, syncope, and orthostatic hypotension,Severe nausea and vomiting (pretreat with antiemetic),Potential for hallucination, dyskinesia, and impulse control disorders,Do not mix with serotonin 5-HT3 antagonists (e.g., ondansetron) due to severe hypotension,Use caution in patients with cardiovascular disease, hypotension, or renal impairment
Hypersensitivity to hydroxyzine or any component,Early pregnancy (first trimester),Porphyria,Breastfeeding (use caution)
Concurrent use with serotonin 5-HT3 antagonists (e.g., ondansetron),Hypersensitivity to apomorphine or sulfite-containing products,Severe asthma or sulfite allergy
Alcohol increases sedation and CNS depression; avoid concurrent use. No significant food interactions, but take with food if GI upset occurs.
Avoid alcohol: may increase drowsiness and hypotension. Grapefruit juice: may increase risk of QT prolongation. No specific food interactions; maintain normal diet but monitor for changes in blood pressure.
First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal withdrawal symptoms (irritability, tremors) with chronic maternal use near term; no evidence of structural anomalies.
Apomorphine hydrochloride is a dopamine agonist indicated for Parkinson's disease. Limited human pregnancy data; animal studies show fetotoxicity and teratogenicity at doses near maternal toxic doses. FDA Pregnancy Category C. First trimester: Avoid use unless benefit outweighs risk. Second/third trimester: No established safety; potential fetal effects include altered dopamine receptor development. Postnatal: Risk of neonatal withdrawal if used near term.
Hydroxyzine is excreted in human milk; M/P ratio not established. Potential for adverse effects in infants (sedation, irritability). Use during breastfeeding only if clearly needed; monitor infant for drowsiness.
No data on apomorphine excretion in human milk. M/P ratio unknown. Due to potential for serious adverse reactions in breastfeeding infants (e.g., somnolence, hypotension, dyskinesia), breastfeeding is not recommended during therapy.
No specific dose adjustments recommended in pregnancy; use lowest effective dose. Hydroxyzine may be less effective if used as an antiemetic due to altered clearance; consider alternative agents.
Pregnancy can alter apomorphine pharmacokinetics due to increased plasma volume, renal blood flow, and hepatic metabolism. No specific dose adjustment guidelines exist. Use lowest effective dose with careful titration. Monitor for reduced efficacy or increased adverse effects (e.g., hypotension, nausea).
VISTARIL (hydroxyzine pamoate) is a first-generation antihistamine with anxiolytic and sedative properties. It is often used for preoperative sedation, pruritus, and anxiety. Onset of sedation is rapid (15-30 minutes) but duration is short (4-6 hours). It has anticholinergic effects; caution in elderly and patients with glaucoma or prostatic hypertrophy. Do not administer intra-arterially or subcutaneously (risk of hemolysis or tissue necrosis). It is not a controlled substance, but has abuse potential. May cause significant somnolence; advise against driving or operating machinery.
Administer subcutaneously; avoid intravenous use due to risk of hemolytic anemia and hypotension. Onset is rapid (5-15 minutes) with short duration (1 hour). Use an antiemetic (e.g., domperidone or trimethobenzamide) for 3 days before starting to prevent nausea. Do not use with 5-HT3 antagonists (e.g., ondansetron) due to profound hypotension. Monitor for dyskinesia, orthostatic hypotension, and QT prolongation. Avoid in patients with dementia, psychosis, or severe respiratory depression; caution in hepatic/renal impairment. Test dose (0.2-0.5 m L) is required before first prescription.
Take as prescribed; do not exceed recommended dose.,May cause drowsiness; avoid driving or heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of allergic reaction (rash, difficulty breathing) immediately.,Do not stop abruptly without consulting doctor.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed; it is for on-demand treatment of 'off' episodes.,Inject under the skin (subcutaneous) as directed; do not inject into a vein or muscle.,You may feel dizzy or lightheaded when standing up; rise slowly from sitting or lying down.,Nausea is common; your doctor may prescribe an anti-nausea medicine to take before each dose.,Report any chest pain, fainting, or severe dizziness immediately.,Avoid alcohol and grapefruit juice while using this medication.,Do not change your dose or frequency without consulting your doctor.,Keep this medication away from children and pets.
No interactions on record
"Coadministration of morphine with palbociclib may increase plasma concentrations of palbociclib due to morphine-induced inhibition of intestinal P-glycoprotein (P-gp) efflux transporter and potential competition for CYP3A4 metabolism. This elevation can heighten the risk of palbociclib-related toxicities, including myelosuppression (neutropenia, leukopenia, anemia), hepatotoxicity, and gastrointestinal adverse effects (e.g., diarrhea, nausea). Patients should be monitored for signs of excessive palbociclib exposure and dose reductions considered if toxicity occurs."
"Morphine, a potent opioid analgesic, can inhibit the metabolism of sulfisoxazole, a sulfonamide antibiotic, by competing for hepatic glucuronidation pathways. This pharmacokinetic interaction leads to increased plasma concentrations of sulfisoxazole, potentially elevating the risk of dose-dependent adverse effects such as crystalluria, hypersensitivity reactions, and bone marrow suppression. Co-administration requires careful monitoring for sulfonamide toxicity, especially in patients with renal impairment or those receiving high-dose morphine."
"Morphine is a potent opioid analgesic that can inhibit the metabolism of isavuconazonium (prodrug of isavuconazole) via competitive inhibition of CYP3A4, the primary enzyme responsible for its activation. This leads to reduced conversion to the active antifungal isavuconazole, potentially decreasing its efficacy against invasive fungal infections. Conversely, isavuconazonium may also inhibit morphine metabolism, increasing opioid side effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISTARIL vs APOMORPHINE HYDROCHLORIDE, answered by our medical review team.
VISTARIL is a Antihistamine that works by Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.. APOMORPHINE HYDROCHLORIDE is a Opioid Agonist that works by Non-ergoline dopamine agonist with high affinity for D2 and D3 receptors, moderate affinity for D4, D5, and adrenergic receptors; activates striatal dopamine receptors to improve motor function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISTARIL and APOMORPHINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISTARIL is: Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.. The standard adult dose of APOMORPHINE HYDROCHLORIDE is: Subcutaneous injection: 0.2 m L (2 mg) test dose, then 0.2-0.6 m L (2-6 mg) as needed for acute hypomobility episodes; maximum single dose 0.6 m L (6 mg). Sublingual: 2-10 mg sublingually as needed, not more than every 2 hours, maximum 30 mg/day. Continuous subcutaneous infusion: 0.5-2.0 mg/hour via infusion pump.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISTARIL and APOMORPHINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISTARIL is classified as Category C. First trimester: Limited human data; animal studies suggest no major teratogenic risk; fetal harm cannot be ruled out. Second and third trimesters: Hydroxyzine may cause neonatal w. APOMORPHINE HYDROCHLORIDE is classified as Category D/X. Apomorphine hydrochloride is a dopamine agonist indicated for Parkinson's disease. Limited human pregnancy data; animal studies show fetotoxicity and teratogenicity at doses near m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.